AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Terminated
Medtronic
Phase 3
2007-12-01
The purpose of this study is to determine whether early atrioventricular node (AVN) ablation
with pacing device therapy will reduce death and hospitalization when compared to the
conventional drug therapy in elderly patients with recurrent and symptomatic atrial
fibrillation (AF).
AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Terminated
Mayo Clinic
Phase 3
2007-12-01
The purpose of this study is to determine whether early atrioventricular node (AVN) ablation
with pacing device therapy will reduce death and hospitalization when compared to the
conventional drug therapy in elderly patients with recurrent and symptomatic atrial
fibrillation (AF).
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg
Completed
Mylan Pharmaceuticals
Phase 1
2006-01-01
The objective of this study was to investigate the bioequivalence of Mylan's verapamil HCl
extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules
following evening administration of a single, oral 300 mg (1 x 300 mg) dose under fasting
conditions.
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg
Completed
Mylan Pharmaceuticals
Phase 1
2006-03-01
The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl
extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules
following evening administration of a single, oral 300 mg (1 x 300 mg) dose administration
under fasting conditions.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
